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Jules-Gonin, Lausanne, Switzerland, 5 Department of Surgical Science, University of Torino, Torino, Italy, 6 Department of
Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania, Italy, 7 Center for Research in
Ocular Pharmacology-CERFO, University of Catania, Catania, Italy
Our study was aimed at assessing the retinal binding of a new synthetic Brilliant Blue G
(BBG) derivative (pure benzyl-Brilliant Blue G; PBB) ophthalmic formulation, to improve
vitreoretinal surgery procedure. Protein affinity of the new molecule was evaluated in vitro
(cell-free assay) and in silico. Furthermore, an ex vivo model of vitreoretinal surgery was
developed by using porcine eyes to assess the pharmacological profile of PBB, compared
to commercial formulations based on BBG and methyl-BBG (Me-BBG). PBB showed a
higher affinity for proteins (p < 0.05), compared to BBG and Me-BBG. In vitro and in silico
studies demonstrated that the high selectivity of PBB could be related to high lipophilicity
and binding affinity to fibronectin, the main component of the retinal internal limiting
membrane (ILM). The PBB staining capabilities were evaluated in porcine eyes in
comparison with BBG and Me-BBG. Forty microliters of each formulation were slowly
placed over the retinal surface and removed after 30 s. After that, ILM peeling was carried
out, and the retina collected. BBG, Me-BBG, and PBB quantification in ILM and retina
tissues was carried out by HPLC analysis. PBB levels in the ILM were significantly (p < 0.05)
higher compared to BBG andMe-BBG formulations. On the contrary, PBB showed amuch
lower (p < 0.05) distribution in retina (52 ng/mg tissue) compared to BBG and Me-BBG, in
particular PBB levels were significantly (p < 0.05) lower. Therefore, the new synthetic Brilliant
Blue derivative (PBB) showed a great ILM selectivity in comparison to underneath retinal
layers. In conclusion, these findings had high translational impact with a tangible improving
in ex vivo model of retinal surgery, suggesting a future use during surgical practice.
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Retinal surgery includes complex techniques aimed at resolving a
variety of conditions, such as macular hole and pucker (also
known as epiretinal membrane), a disease that affects the central
retina (called macula). The use of vital dyes to stain the retina
during ocular surgery is necessary for visualization and removal
of thin and transparent membranes, such as the internal limiting
membrane (ILM). The mechanism of action of vital dyes rest on
binding and staining of proteins, without killing cells (Delaey
et al., 2000; Desmettre et al., 2000). Specifically, in vitreoretinal
surgery, vital dyes bind and stain ILM proteins, such as
fibronectin, a component of extracellular matrix (Rodrigues
et al., 2009). The ILM is the boundary between the vitreous
body and the retina, and includes the feet of Müller cells and
astrocytes (Heegaard et al., 1988). In the central retina, the ILM
thickness is around 400 nm; and ILM is characterized by a
fibrillar meshwork of different type of collagen fibers surrounded
mainly by hyaluronic acid (Heegaard et al., 1988). ILM is a
basement membrane that acts as a double-sided sticky tape
interface between the vitreous and retina, assisting also the
alignment of the Müller cells to the optical axis of the eye
(Balasubramani et al., 2010). ILM functions appear non-
necessary in the adult eye, and ILM peeling is generally carried
out without relevant post-surgery complications (Uechi et al.,
2014). The ILM removal has been introduced as adjuvant
surgical procedure to improve anatomic and functional
outcomes during surgery for macular hole (Lois et al., 2011)
and epiretinal membrane (Schechet et al., 2017). Vital dyes for
the ILM staining are commonly used in vitreoretinal surgery as
ultrashort-acting pharmacological tools, that are used once orFrontiers in Pharmacology | www.frontiersin.org 2more times during the surgery, and then removed few seconds
after administration (Januschowski et al., 2018). Despite the
widespread use of these molecules in retinal surgery, unmet
medical needs still remain unsolved, such as selectivity for ILM
and safety. Therefore, surgeons are looking for new molecules
capable to selectively stain the ILM, with low affinity (low extend
of absorption) to adherent retinal layers, in order to avoid
potential cytotoxicity on off-target tissues (Figure 1). Protein
binding of Brilliant Blue G (BBG), a dye widely used in
vitreoretinal surgery (Kawahara et al., 2007; Remy et al., 2008)
instead of green indocyanine (potentially toxic to retina), was
reported to be mainly guided by hydrophobic interactions
(Georgiou et al., 2008). Therefore, we aimed at designing and
synthetizing new BBG derivatives, with high lipophilicity in
order to improve ILM protein binding affinity, and to avoid
diffusion into retinal layers adherent to ILM. We further tested
the ILM protein affinity of the new pure benzyl-BBG (PBB®) in
comparison with BBG and methyl-BBG (Me-BBG), already in
the market. Particularly, in vitro, in silico, and ex vivo
experimental approaches were aimed to investigate the
pharmacological profile of these molecules.METHODS
Synthesis
All chemicals used for the synthesis (reagent grade) and
chromatographic analysis (HPLC grade) were obtained from
Sigma-Aldrich/Merck (Milan, Italy). The synthesis of BBG
derivatives (alkyl- and benzyl-BBG series, Table 1, Figure 2)
was carried out as previously reported in the patent (David,A B
FIGURE 1 | Passive diffusion of molecules from the inner limiting membrane (ILM) to the retina (RET). (A) Diffusion of a molecule with low affinity to ILM proteins. (B)
Diffusion of a molecule with high affinity to ILM proteins.May 2020 | Volume 11 | Article 708
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(Figure 2). The microwave-assisted reactions were done using
a CEMDiscover Systemmicrowave synthesizer (CEM, Cologno
al Serio, Bergamo, Italy). Briefly, for the synthesis of alkyl-BBG
series (Table 1, entry 2–6) the reaction mixture was stirred and
irradiated in the microwave synthesizer, and the following
conditions were kept constant during 30 min reaction step:
80°C, 150 W, using as solvent MeOH/H2O mixture (1/1 v/v).
Reaction steps for alkyl series of BBG derivatives were within 5–
7 steps. After each step, the reaction vessel was cooled to room
temperature and appropriate aliquots of alkylating agent and
NaOH were added to the reaction mixture. The overall yields of
the aliphatic-N-alkyl derivatives of BBG were within 70–95%.
The synthesis of benzylic BBG derivatives (Table 1, entry 7–12)
was completed within 5–15 min. Briefly, 0.04 mmol of BBG, 1.2
mmol of benzyl-bromide, 1.2 mmol of NaOH, and catalytic
amount of KI were added to 4 ml of 1/1 v/v methanol/water
mixture. Then, the mixture was irradiated with (150 W)
microwaves at 80°C. The overall synthesis yields of the N-
benzyl derivatives of BBG were within 80–95%. Alkyl- and
benzylic-BBG compounds were purified with flash-
chromatography on silica gel, by using a CH2Cl2/MeOH
gradient. Purity of compounds was within 96–99% as
determined by HPLC in our lab (data not shown).
Protein Affinity
In order to have the same dye/protein molar ratio for dye protein
affinity assay, a set of molecular weight standards was obtained
by mixing 430 nmol of the following proteins: i. fibronectin
proteolytic fragment 45 kDa; ii. E. coli beta-galactosidase 116.3
kDa; iii. bovine serum albumin 66.5 kDa; iv. chicken ovalbumin
42.7 kDa; v. equine cytochrome C 12.3 kDa. Polyacrylamide gel
electrophoresis was carried out loading the molecular weight
standard in a 9% precast gels (Biorad), as triplicates on separate
lanes. Gel electrophoresis was carried out at 20V for 60–90 min
in denaturing conditions. After runs, each lane was cut and
soaked overnight in a different staining solution, consisting of
dyes dissolved at 0.025% in gel fixative solution (40% methanol,
20% acetic acid). Thereafter, gel lanes were decolored in the
fixative solution without dyes, until the background stain
reached the minimum level compared to stained protein
bands. Images were collected with a scanner at 300 dpi, 16M
colors. Densitometric analysis was done using the software
ImageJ (Rueden et al., 2017). LogD values (pH 7.4) were
calculated in silico using ACD/Labs software (version 11.1TABLE 1 | List of designed and synthetized molecules bearing different
substituents in the diphenyl nitrogen of Brilliant Blue G (BBG) *pH = 7.4.
Entry —R LogD* MW Formula
1 —H 0.50 854.02 C47H48N3NaO7S2
2 —CH3 0.57 868.05 C48H50N3NaO7S2
3 —CH2-CH3 1.08 882.08 C49H52N3NaO7S2
4 —CH2-CH2-CH3 1.58 896.11 C50H54N3NaO7S2
5 —CH2-CH2-OH −0.77 898.08 C49H52N3NaO8S2












3.90 1000.26 C58H62N3NaO7S2FIGURE 2 | Synthesis scheme of new Brilliant Blue G (BBG) derivatives.May 2020 | Volume 11 | Article 708
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affinity of tested vital dyes with predicted binding affinity for
fibronectin, one of the main components of ILM, we carried out
molecular docking and molecular mechanics generalized born
surface area (MM-GBSA) calculations on vital dyes/fibronectin
domain complexes. For this purpose, we retrieved from Protein
Data Bank repository (https://www.rcsb.org/) the structure of the
gelatin binding domain (GBD) of fibronectin (PDB: 3M7P)
(Graille et al., 2010). The structure of vital dyes was obtained
with the online SMILES translator and structure file generator of
NIH Cancer Institute (https://cactus.nci.nih.gov/translate/). The
monomer of fibronectin PDB was subjected to the protein
preparation task of Schrödinger® maestro. Ionization state of
residues was assigned at pH 7.4 with Epik®, and then protein was
subjected to energy minimization protocol. Sitemap® was used
for identification of binding pockets of GBD fibronectin
monomer. Docking grid was centered on the biggest pocket of
GBD, then, docking of vital dyes on GBD was carried out with
the standard precision (SP) docking (Schrödinger®) performed
with Glide (Schrödinger®). The DGbinding of vital dyes to
fibronectin GBD was predicted with MM-GBSA calculation;
for this purpose, the VSGB 2.0 solvation model was used and
all residues within 15 Å from the ligand were capable to move
during application of the minimization energy gradient.
Prediction of BBG derivatives ADME properties was carried
out with the webserver SwissADME (http://www.swissadme.
ch/).
Ex Vivo Study
Ex vivo model of vitreoretinal surgery has been previously
reported for evaluation of indocyanine green ILM staining
properties (Nakamura et al., 2003). We carried out on swine
eyes the same procedure previously reported on primates, with
slight modifications. The following formulations have been
tested in the ex vivo model of vitreoretinal surgery: Brilliant
Peel™ (0.025% Brilliant Blue G BBG; Fluoron, Ulm, Germany);
ILM-Blue™ (0.025% Brilliant Blue G; Dutch Ophthalmic
Research Center (International) B.V, Agrate Brianza, Italy);
View-ILM® (0.03% methyl-Brilliant Blue G; Alchimia, Ponte
San Nicolò—Padova, Italy); PBB® (0.05% Pure benzyl-Brilliant
Blue G; Alfa-Instruments, Casoria, Italy). Along with primates,
the swine retina represents the closest resemblance with the
human one. Post-mortem swine eyes were obtained from a local
slaughterhouse (Department of Veterinary Prevention, Section
of Hygiene and Food of Animal Origin, Catania, Italy) by vet
supervision (Dr. Antonio Augello); since the eyes were
enucleated post-mortem an ethical review process was not
required for the present study. Immediately after collection, the
eye was placed in a large tube containing BSS solution and
transported to the lab. The eye was placed on a glass holder and a
360-degree limbal incision was carried out in order to remove
cornea, aqueous, iris ciliary-body, and lens. The vitreous was
gently extracted, under operating microscope, with cotton buds
and 23-gauge forceps. After core vitreous removal a posterior
vitreous detachment was performed. The globe was filled with 2
ml of BSS, then, 40 µl of each formulation were slowly placedFrontiers in Pharmacology | www.frontiersin.org 4over the retinal surface. After 30 s, formulation along with BSS
was removed and the retinal surface was rinsed with fresh BSS.
The peeling of ILM was carried out by 23-gauge forceps in order
to grasp the membrane, and thereafter, the retina underneath the
area of peeled ILM was collected. After tissue collection, samples
were weighted and stored at −20°C till analysis. The levels of the
dye molecules were quantified by means of HPLC analysis.
High Performance Liquid Chromatography
(HPLC) Analysis
ILM and RET tissue samples obtained as described above were
homogenized in 250–500 ml of methanol using a micro tissue
grinder. Samples were subjected to sonication, carried out with a
Branson Sonifier. After that, the samples were centrifuged at
1,000 g for 10 min and filtered on 0.45 mm syringe filters (0.45-
mm Spartan filters, Schleicher and Schuell, Dassel, FRG). The
filtrates were transferred into clean test tubes and subjected to a
gentle stream of nitrogen till dryness. The dried residue was
reconstituted in 100 ml of mobile phase by vortexing for 120 s,
filtered again on 0.45 mm filters, and, finally, 10–20 ml aliquots
were injected into the chromatographic apparatus (each sample
was analyzed in triplicate).
HPLC analyses were performed on an Agilent 1260 Infinity II
chromatographic system (Agilent Technologies) equipped with a
ChemStation OpenLab software (M8307AA), a quaternary pump
(G7111B), a diode array detector (DAD, G7111B), and a
thermostated column compartment (G1316A). Chromatographic
separations were performed using a Kinetex XB-C18 column (100
Å, 100 mm × 4.60 mm, 2.6 mm, Phenomenex). BBG, Me-BBG, and
PBB® were analyzed using three different isocratic ternary mobile
phases consisting of (A) acetonitrile, (B) methanol, and (C)
triethylamine 0.3% (v/v) in water (pH adjusted to 3.0 with
trifluoroacetic acid) with different proportions (A:B:C) as follows:
BBG 49:5:46 (v/v/v); Me-BBG 54:5:41 (v/v/v); PBB® 62:5:33 (v/v/
v). The flow rate was set at 0.5 ml/min and the column was
thermostated at 24°C during the analysis. UV spectra were
recorded in the range 200–800 nm and chromatograms were
acquired at 613 and 316 nm. The analytical method was validated
according to ICH guidelines (ICH Guideline, 2005).
Identification of the dye molecules (BBG, Me-BBG, and PBB®)
was determined by HPLC–DAD analysis by comparing the
retention times and the UV spectra of the analyzed samples
with those of reference standards. Potential interferences from
endogenous matrix constituents of ILM and RET tissues were
excluded by analyzing the chromatograms of control tissues
(untreated eyes), used for HPLC calibration. Furthermore,
peak-purity tests (Gilliard and Ritter, 1997; Stahl, 2003) were
used to demonstrate the absence of coeluting peaks. Peak-purity
tests were done with OpenLab software (Agilent Technologies)
using photodiode-array detector spectra. Eleven-point
calibration curves were set up for all standards to test the
linearity of the UV-DAD response. Linear regression was
performed, using OpenLab software (Agilent Technologies), on
the calibration data points of each dye tested to determine slope,
intercept, and correlation coefficient (R2). Calibration standards
were prepared by spiking 10 ml of appropriate working solutionsMay 2020 | Volume 11 | Article 708
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and retinal samples. Calibration standards were processed as
reported in the sample preparation procedure and analyzed by
HPLC. The limits of detection (LOD) and quantification (LOQ)
were determined in biological samples spiked with progressively
lower concentrations of the analytes. The LOD and LOQ were
established with an S/N ratio of 3:1 and 10:1, respectively (n=6).
Precision and accuracy were determined at three concentration
levels in ILM and RET within the calibration range by assaying
replicates (n = 5) of samples spiked with the three tested dyes
(25,800 and 12,800 ng/ml), and processed as the unknowns. To
determine intra- and inter-day precision and accuracy, matrix
samples were analyzed in replicates on the same day and on three
different days, respectively. Intra- and inter-day precision was
reported as relative standard deviation (RSD%), with an
acceptability limit set at ≤15%. Accuracy was calculated by
comparison of mean assay results with the nominal
concentrations, with acceptability limits set at ±15%.
Statistical Analysis
Data are expressed as mean ± SD values, n=8. Statistical analysis
was carried out with application of one-way ANOVA, followed
by Tukey post-hoc test, for multiple comparison between groups.
Differences between groups were considered statistically
significant given p-values <0.05. Statistical analysis and graph
design were carried out with GraphPad Prism 7.0 (San Diego,
CA, USA).RESULTS
Synthesis
Microwave-assisted synthesis is a well-established approach to
decrease reaction times and increase yields of several reactions in
organic synthesis (Kappe, 2004). In fact, the reaction time for the
synthesis of the alkyl-BBG series (Table 1, Figure 2) by
microwave assisted synthesis was within 0.5–4 h, compared to
longer reaction time (168–192 h, data not shown) of
conventional synthetic approaches. Also for the benzylic BBG
derivatives (Table 1, Figure 2) the designed microwave-assisted
synthesis ensured very fast reaction rate within 5–15 min
(David, 2019).
Design of Synthetic Dyes
In a simplified model of dye retinal distribution (Figure 1), the
key factors are: (i) the passive diffusion process that, according to
the Fick’s Law, depends on concentration gradient and diffusion
coefficient of the dye; (ii) the dye binding affinity to ILM proteins.
The balance between these two factors affects the retinal
distribution of the dye. Our goal was to design BBG derivatives
with higher binding affinity to ILM proteins, in order to get an
ILM trapping of the new dyes, and avoiding dye migration to
retinal layers (Figure 1, panel B). BBG binds the main proteins of
ILM, collagen IV, laminin, and fibronectin (Duhamel, 1983)
forming a blue dye-protein complex (Compton and Jones, 1985).
BBG binds to protein with a combination of electrostatic andFrontiers in Pharmacology | www.frontiersin.org 5hydrophobic interactions. The heteropolar bonding occur
between the sulfonic groups of BBG and basic amino acids of
proteins (Lys, His, and Arg) (Tal et al., 1985). Importantly, other
studies suggest that hydrophobic forces play a major role in the
interactions between BBG and aromatic amino acid protein
residues (Phe, Tyr, Trp) (Compton and Jones, 1985; Georgiou
et al., 2008; Katrahalli et al., 2010). For these reasons, we
synthesized a series of BBG derivatives, by introducing alkyl-
or benzyl-moieties on the diphenylic nitrogen of BBG, in order to
increase lipophilicity and the number of putative hydrophobic
interactions of BBG derivatives with proteins of ILM (Caron
et al., 2006). We identified the benzyl-BBG derivative (PBB®,
Table 1, logD=2.20) as the best candidate to be further
developed, bearing physical-chemical properties that lead to a
balance between lipophilicity and water solubility. Furthermore,
the arylic moieties, compared to alkyl-moieties, can ensure
increasing non-covalent interactions by means of p-bonds (p
stacking, polar-p, cation-p, and anion-p), with aromatic residues
of proteins (Ward and Beswick, 2014). The higher lipophilicity of
the PBB®, combined with a suitable concentration, ensured
higher binding affinity to ILM proteins, avoiding relevant dye
migration to retinal layers (Figure 1, panel B), as demonstrated
by the ex vivo studies.
Protein Interaction
The PBB® binding, quantified as staining intensity, to proteins
bands analyzed with SDS-page was significantly higher (p < 0.05),
compared to BBG (Figure 3). Driving forces of BBG binding to
proteins is generally attributed to hydrophobic and Van der Waals
interactions, and to some extent also to bonds of sulphonic anion
group with basic and polar residues (Georgiou et al., 2008).
Particularly, it was also reported that hydrophobic forces play a
major role in the interaction between BBG and BSA (Compton
and Jones, 1985; Katrahalli et al., 2010). We found that PBB® had
higher protein affinity (% staining) compared to BBG and Me-
BBG (Figure 3). Predicted logD values (pH 7.4) showed that PBB®
has higher lipophilicity (LogD = 2.2) compared to BBG (LogD =FIGURE 3 | Protein binding [% of control Brilliant Blue G (BBG)]. Pure
benzyl-Brilliant Blue G (PBB) binds with higher affinity to proteins, compared
to BGG and methyl-Brilliant Blue G (Me-BBG). *p < 0.05 vs. BBG; †p < 0.05
vs. Me-BBG.May 2020 | Volume 11 | Article 708
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weight glycoprotein (400–500 kDa), is the main component of
ILM, and its expression in ILM is increased in elderly and diabetic
patients (Ljubimov et al., 1996; To et al., 2013). The in silico study
confirmed that PBB® binding to fibronectin is mainly driven by
hydrophobic interactions, in comparison to BBG and Me-BBG.
Furthermore, this result fits with in vitro data and prediction of
LogD. We predicted dye binding affinity for fibronectin, through
combination of ligand docking andMM-GBSA calculation. PBB®,
BBG and Me-BBG were docked to the monomer of GBD of
fibronectin (Graille et al., 2010). After docking, complexes were
subjected to MM-GBSA calculation in order to predict the affinity
of vital dyes to fibronectin. The predicted DGbinding of PBB®
(−128,32 Kcal/mol) to fibronectin GBD was significantly lower
(more negative, more favorable) compared to Me-BBG (−54.28
Kcal/mol) and BBG (−71.22 Kcal/mol). Furthermore, the LogD
(lipophilicity index) correlated with mean percentage (%) of dye
protein binding (Figure 3, 100 was set for BBG), predicted
DGbinding and also docking strain energy; although the dataset is
limited to three congeneric dyes (Figure 4). Furthermore, the
predicted receptor docking strain energy (the energy of receptor
after binding to compounds) inversely correlated with LogD
(Figure 4) and increasing steric hindrance of R (Figure 5) in
BBG (14.1 Kcal/mol), Me-BBG (11.5 Kcal/mol), and PBB® (3.2
Kcal/mol). Moreover, as shown in Figure 5, PBB® bound to
fibronectin interacts through Van der Waals interactions with
more hydrophobic residues (green residues) of fibronectin GBD,
compared to BBG andMe-BBG. ADME prediction confirmed that
all compounds: i. are poorly soluble; ii. do not cross the BBB
barrier because they are all substrates of p-glycoprotein drug efflux
pump; and iii. are not metabolized by cytochromes P450 (1A2,
2C19, 2C9, 2D6, 3A4). Due to series of violations of Lipinski rule
all the tested BBG derivatives are no drug-like compounds,
although BBG is a potent selective non-competitive antagonist
of purinergic ionotropic P2X7 receptor (Bartlett et al., 2014).
HPLC Method Validation
Under the chromatographic conditions reported in the Methods
section, the retention times of BBG, Me-BBG, and PBB® were
4.68, 4.58, and 4.69, respectively. The correlation coefficients for
standards of all dyes included in the matrices ILM and RET
(from untreated eyes) were higher than 0.9999 and the y-Frontiers in Pharmacology | www.frontiersin.org 6intercept values were relatively low (Table 2). The LOD values
in analyzed tissues ILM/RET were 9.85/10.10, 10.10/9.90, and
9.57/9.34, for BBG, Me-BBG, and PBB®, respectively. While, the
LOQ values in ILM/RET were 29.84/30.29, 30.59–30.00, and
29.01–28.30, for BBG, Me-BBG, and PBB®, respectively (Table
2). The acceptability criterion recommended by ICH guidelines
was reached for all obtained analytical data, with overall intra-
and inter-day RSD% not exceeding 6%, and accuracy values
within the 95.5–103.5% range (data not shown). These results
demonstrated that the used analytical method was reproducible
and reliable for biological analyzed samples.
Porcine Eye Model
The ex vivo model of vitreoretinal surgery has strengthened the
data of in vitro cell free dye protein binding affinity study. Through
the ex vivomodel of vitreoretinal surgery we evaluated the binding
of tested dye formulations to ILM and retina (Figure 6). Dye
quantification was carried out with HPLC in isolated retinal
tissues. HPLC analysis confirmed that PBB® was the dye that
selectively accumulated with higher concentration in ILM,
compared to the retina (RET), after ILM peeling procedure. In
fact, PBB® levels, detected in the ILM, were significantly (p < 0.05)
higher, with 2.9- and 6.0-fold increase, compared to BBG (Brilliant
Peel™, ILM Blue™) and Me-BBG (View ILM®) formulations,
respectively. PBB® formulation provided higher, even though not
statistical significant levels of dye content in ILM compared to
Brilliant Peel™ formulation (BBG). It is worthy of note, that the
PBB® formulation was mainly selective for ILM staining and did
not cross this membrane, in fact, PBB® retinal distribution was
significantly lower (p < 0.05) compared to other tested
formulations. The administration of the 0.05% PBB®
formulation, in the ex vivo model of vitreoretinal surgery,
provided dye levels of 52 ng/mg in the retina. Compared to
PBB®, the retinal levels of the other tested formulations ILM
Blue™ (BBG), View ILM® (Me-BBG), and Brilliant Peel™ (BBG)
were 7.9, 4.3, and 3.3-fold higher, respectively.DISCUSSION
In general, the use of vital dyes in vitreoretinal surgery is very
common and represents an important tool during the surgicalA B
FIGURE 4 | Hydrophobic interactions are the driving forces of dye binding affinity to proteins. (A) Upper quadrant LogD vs experimental % dye protein binding (for
BBG, the % values were set to 100), bottom quadrant LogD vs predicted dye DGbinding to fibronectin; (B) LogD vs docking strain energy of dyes bound to
fibronectin.May 2020 | Volume 11 | Article 708
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C
FIGURE 5 | Pure benzyl-Brilliant Blue G (PBB) forms with fibronectin more hydrophobic contacts than Brilliant Blue G (BBG) and methyl-Brilliant Blue G (Me-BBG).
(A) BBG pose; (B) Me-BBG pose; (C) PBB pose.TABLE 2 | Calibration data, limits of detection (LOD), and quantification (LOQ) obtained by High Performance Liquid Chromatography (HPLC) analysis.
Matri Dye Regression equation R2 Linear range LOD LOQ
y=peak area, x=ng/ml (ng/ml) (ng/ml) (ng/ml)
ILM BBG y = 0.17014693·x+0.5023796 0.99999 0.7800–12,800 9.85 29.84
Me-BBG y = 0.17444827·x+0.5150798 0.99998 0.7800–12,800 10.10 30.59
PBB® y = 0.16301218·x+0.4812452 0.99999 0.7800–12,800 9.57 29.01
RET BBG y = 0.17273799·x+0.5100300 0.99998 0.7800–12,800 10.00 30.29
Me-BBG y = 0.17102771·x+0.504980 0.99998 0.7800–12,800 9.90 30.00
PBB® y = 0.16135010·x+0.475048 0.99999 0.7800–12,800 9.34 28.30Frontiers in Pharmacology | www.frontiersin.org 7 May 2020 | Volume 11 | ArBBG, Brilliant Blue G; Me-BBG, methyl-Brilliant Blue G; PBB®, pure benzyl-Brilliant Blue G; ILM, inner limiting membrane; RET, retina.ticle 708
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not supposed to damage the stained cells, however, in the past,
some concerns about potential retinal toxicity has been raised
(Röhrig et al., 2019). Awareness about vital dyes safety was
mainly related to dye uptake and retention in retinal layers,
underneath to the ILM (Cheng et al., 2005). Before the spread of
BBG, indocyanine was the most common used molecule in
vitreoretinal surgery. Indocyanine toxicity was accounted to
non-selective compound uptake into retinal structures
underneath the ILM, such as Müller cells (Haritoglou et al.,
2002). The potential toxic effects of indocyanine led to
development of BBG as new molecule for vitreoretinal surgery.
BBG shows a good safety profile in vitro and in vivo on Müller
cells (Kawahara et al., 2007) and retinal ganglion cells,
respectively (Remy et al., 2008). In the present study, we
designed a BBG derivative with high selectivity for retinal ILM,
and poor selectivity for the other retinal structures, underneath
the ILM. Retinal binding of the new BBG derivative (PBB®) has
been assessed by in vitro, in silico, and ex vivo models.
Accordingly to this multidisciplinary approach, the present
study would have a great translational impact, because the
results generated from the bench can be translated to the
clinical practice. In order to design new BBG derivatives with
high ILM affinity, we synthesized a series of BBG derivatives by
introducing alkyl or benzyl moieties at the diphenylic nitrogen of
BBG, bearing increasing lipophilicity, without affecting the
chromophore and staining properties (Table 1, Figure 2)
(David, 2019). Brilliant Blue G, Me-BBG, and PBB®, among all
BBG derivatives, were tested to confirm that increased molecule
lipophilicity resulted also in greater ILM staining selectivity. An
in vitro cell free binding affinity assay, an in silico study, and an
ex vivo model of vitreoretinal surgery were used to figure out the
pharmacological profile of BBG, Me-BBG, and PBB®. Our in
vitro and in silico studies confirmed that BBG derivatives binding
affinity for proteins, such as fibronectin, is mainly driven by
hydrophobic interactions (Georgiou et al., 2008). The ex vivo
study confirmed that increased molecule lipophilicity and
protein binding/staining lead to increased ILM selectivity ofFrontiers in Pharmacology | www.frontiersin.org 8the dye. The ILM is characterized by a well-organized
tridimensional network of proteins. Most important proteins
that are included in the 3-D scaffold of ILM are type IV collagen,
fibronectin, laminin, nidogen-1, and heparan sulfate
proteoglycans (agrin, perlecan, and collagen XVIII). In elderly
subjects, fibronectin, collagen IV, agrin, and laminin are
abundant (Kohno et al., 1987b). In diabetic patients the
thickness of ILM is reported to be higher than healthy subjects
(To et al., 2013). Furthermore, fibronectin was overexpressed in
ILM of diabetic patients, along with tenascin (Kohno et al.,
1987a; Russell et al., 1991; Roy et al., 1996; To et al., 2013;
Peynshaert et al., 2019). Indeed, fibronectin due to its abundance
in ILM of elderly and diabetic patients, along with collagen,
represents the main target of vital dyes used in vitreoretinal
surgery. Therefore, we assessed the protein affinity of BBG
derivatives through SDS-page of standard proteins such as
fibronectin, E. coli beta-galactosidase, bovine serum albumin,
chicken ovalbumin, and equine cytochrome C. PBB® showed the
highest affinity, quantified as protein staining intensity after
SDS-page electrophoresis (Figure 3). We also carried out an in
silico study, to support the hypothesis that increased dye
lipophilicity would increase the protein binding affinity and
hydrophobic interactions in the dye-fibronectin complex
(Figures 4 and 5). Therefore, BBG derivatives binding to
fibronectin was predicted through computational studies, i.e.
molecular docking and MM-GBSA calculation. For this purpose,
we retrieved the structure of the GBD of fibronectin (Graille
et al., 2010). The new synthetic dye PBB® showed the higher
affinity for proteins used in the SDS-page assay, as well as
predicted affinity for GBD of fibronectin, compared to the
other tested BBG derivatives. These results are related to the
high PBB® hydrophobicity, (Figure 4). Furthermore, PBB®
binding to proteins, expressed in the ILM, was confirmed by
the ex vivomodel of vitreoretinal surgery. PBB® showed a higher
ILM selectivity and a negligible retinal absorption, compared to
BBG and Me-BBG (Figure 6). In other words, the PBB® ensured
a better interaction with ILM proteins, leading to dye entrapment
in ILM, with reduced diffusion to other retinal layers (Figure 1).FIGURE 6 | Retinal internal limiting membrane (ILM) and underneath retinal layers dye distribution in porcine eye. Brilliant Peel (Brilliant Blue G), ILM Blue (Brilliant
Blue G), View ILM (methyl-Brilliant Blue G), and PBB (Pure benzyl-Brilliant Blue G). *p < 0.05 vs. Brilliant Peel, ILM Blue and View ILM; †p < 0.05 vs. ILM Blue and
View ILM.May 2020 | Volume 11 | Article 708
Spadaro et al. BBG Derivative in Retinal SurgeryThe ex vivo paradigm set-up in the present study is reliable,
cheap, and mimics clinical conditions allowing to evaluate the
dye distribution in retinal membranes with high levels of
accuracy. The ideal dye for vitreoretinal surgery should be a
high grade of purity compound, in order to avoid any potential
interference during surgery. It has been reported that retinal
damage can occur after treatment with vital dyes, and this is
linked to the passive absorption of molecules in the retinal layers
underneath the ILM (Kanda et al., 2004; Kawahara et al., 2007;
Ueno et al., 2007; Maia et al., 2009; Ejstrup et al., 2012; Savary
and Kodjikian, 2014; Almeida et al., 2015; Hurst et al., 2017)
(Figure 1). On the basis of predicted ADME properties of PBB®
the risk of iatrogenic retinal damage is very low, also due to poor
absorption into the retina. The new molecule PBB®, due to its
physical-chemical characteristics and binding properties, is
sequestrated by the retinal ILM, with negligible passive
diffusion in the underneath retinal layers. In conclusion, these
findings had high translational impact suggesting that the new
molecule could be useful in retinal surgical practice, even though
clinical trials would be warranted in order to assess safety and
efficacy profile.Frontiers in Pharmacology | www.frontiersin.org 9DATA AVAILABILITY STATEMENT
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